Can we change the signals we measure to better understand disease?

Sangeeta Bhatia joins David Berry to discuss new approaches to cancer detection, synthetic biomarkers and the promise of hepatocytes as liver cell therapies. They also explore lessons from Satellite Bio and the Faculty Founder Initiative’s work helping more women turn academic research into companies.

Watch on YouTube: https://youtu.be/zTWQN4gE4pc
More conversations: https://www.averincapital.com/averin-insights

00:00 Introduction

01:07 Early versus wrong

02:20 Rethinking liquid biopsy

07:56 Synthetic biomarkers

13:48 The future of home screening

15:45 Hepatocytes and liver therapies

21:13 The Faculty Founder Initiative

28:14 Models for building companies

30:30 Academia and entrepreneurship

32:26 Women and the founder ecosystem

35:08 Advice for the next generation

38:14 Closing reflections

Michael Hasselberg, Chief Transformation and Digital Officer at Nebraska Medicine, joins David Berry for a practical conversation about how health systems are building and adopting AI.

They discuss administrative automation, data governance, the safeguards needed for clinical applications, and how hospitals decide when to build, buy, or rely on existing platforms. Michael also shares his vision for ambient patient rooms, wireless monitoring, and robotics—and why human connection and cybersecurity remain central to care.

Watch on YouTube⁠⁠

Episode page⁠

Averin Capital backs and builds early-stage companies transforming human health through AI and breakthrough technology.⁠

Explore Averin Capital

How do you build an AI-native R&D organization without losing the scientific judgment that makes drug development possible?

Andy Plump, President of Research & Development at Takeda, joins David Berry on Averin Insights to discuss how technology is changing drug discovery and development.

They explore the role of basic science, the changing global research landscape, and how R&D leaders can combine speed, technology, and clinical understanding to bring new medicines to patients.

Watch on YouTube
Episode page

Averin Capital backs and builds early-stage companies transforming human health through AI and breakthrough technology.
Explore Averin Capital

How do strategic investors identify promising science and help turn it into a company?

Christian Schubert, Vice President and Global Head of AbbVie Ventures, joins David Berry on Averin Insights to discuss early-stage biotech investing, working with founders, and where AI can make a meaningful difference in drug discovery.

The conversation explores how corporate venture capital is evolving, how investors build conviction in emerging biology, and what it takes to move scientific ideas toward new medicines.

Watch on YouTube
Episode page

Averin Capital backs and builds early-stage companies transforming human health through AI and breakthrough technology.
Explore Averin Capital

What if medicine could act before symptoms appear?

Thierry Bernard, CEO of QIAGEN, joins David Berry on Averin Insights to explore how diagnostics could help healthcare move from reacting to disease toward earlier detection and more personalized care.

They discuss molecular diagnostics, AI, liquid biopsies, and predictive biology—and the work needed to turn new biological signals into useful information for patients and clinicians.

Watch on YouTube
Episode page

Averin Capital backs and builds early-stage companies transforming human health through AI and breakthrough technology.
Explore Averin Capital

Averin’s David Berry joins Rony Abovitz, Josh DeFonzo, and Chris Morley to explore how robotics, AI, and augmented reality are expanding surgeons’ capabilities. The discussion covers precision and consistency in care, the role of patient demand in adoption, and the next frontier of intervention at the cellular and tissue level.

Averin’s David Berry joins John Bishai, Paul Kinsella, and Will Herrmann to explore exit strategies for healthcare and biotech companies. The discussion covers M&A trends, the outlook for IPOs in 2026, what buyers and investors look for, and how companies can position themselves for a successful exit.

Averin’s David Berry joins Peter Hutt, David Shulkin, and Daniel Troy to explore how regulation, AI, and geopolitics are shaping healthcare and biotech. The discussion covers FDA enforcement trends, the challenges of evaluating AI-enabled products, and shifting global supply chains - and what they mean for innovators.